BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-contents reagents. In addition, it engages in the production and sell of medical devices. BioNote, Inc. was founded in 2003 and is headquartered in Hwaseong-si, South Korea.
Frequently asked questions
What sector does BioNote Inc. (377740) operate in?
BioNote Inc. belongs to the Healthcare sector and operates in the Medical Devices industry.
What is BioNote Inc. (377740) current stock price?
As of the latest data, BioNote Inc. stock price is ₩4,520, with a previous close of ₩4,610. BioNote Inc. lost -₩90 in the last trading session, representing a -1.95% loss.
What is BioNote Inc. (377740) current market capitalization?
BioNote Inc. market cap is approximately 456.13 billion.
What is BioNote Inc. (377740) Earnings Per Share (EPS)?
The trailing EPS is -₩1,245.
What is BioNote Inc. (377740) EBITDA?
BioNote Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 28.76 billion.
Does BioNote Inc. (377740) pay dividends?
Yes. BioNote Inc. pays annual dividends with an annualized yield of 5.04% and an estimated annual payout of ₩228 per share.
When is the next ex-dividend date for BioNote Inc. (377740)?
The next ex-dividend date is scheduled for March 30, 2027.
What is BioNote Inc. (377740) beta (volatility) score?
BioNote Inc. has a beta of 0.579, indicating lower volatility than the overall market.
